Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/211921
Title: | Emerging Agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline? |
Author: | Martinez Peinado, Nieves Cortes Serra, Núria Losada Galván, Irene Alonso Vega, Cristina Urbina, Julio A. Rodríguez, Ana VandeBerg, John L. Pinazo, Maria-Jesus Gascón i Brustenga, Joaquim Alonso Padilla, Julio |
Keywords: | Malaltia de Chagas Malalties parasitàries Chagas' disease Parasitic diseases |
Issue Date: | 19-Jul-2020 |
Publisher: | Informa Healthcare |
Abstract: | ntroduction: Chagas disease treatment relies on the lengthy administration of benznidazole and/or nifurtimox, which have frequent toxicity associated. The disease, caused by the parasite Trypanosoma cruzi, is mostly diagnosed at its chronic phase when life-threatening symptomatology manifest in approximately 30% of those infected. Considering that both available drugs have variable efficacy by then, and there are over 6 million people infected, there is a pressing need to find safer, more efficacious drugs. Areas covered: We provide an updated view of the path to achieve the aforementioned goal. From state-of-the-art in vitro and in vivo assays based on genetically engineered parasites that have allowed high throughput screenings of large chemical collections, to the unfulfilled requirement of having treatment-response biomarkers for the clinical evaluation of drugs. In between, we describe the most promising pre-clinical hits and the landscape of clinical trials with new drugs or new regimens of existing ones. Moreover, the use of monkey models to reduce the pre-clinical to clinical attrition rate is discussed. Expert opinion: In addition to the necessary research on new drugs and much awaited biomarkers of treatment efficacy, a key step will be to generalize access to diagnosis and treatment and maximize efforts to impede transmission. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1080/13543784.2020.1793955 |
It is part of: | Expert Opinion on Investigational Drugs, 2020, vol. 29, num.9, p. 947-959 |
URI: | http://hdl.handle.net/2445/211921 |
Related resource: | https://doi.org/10.1080/13543784.2020.1793955 |
ISSN: | 1354-3784 |
Appears in Collections: | Articles publicats en revistes (Biologia, Sanitat i Medi Ambient) Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
253009.pdf | 789.94 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.